Company (Symbol)* | University/Non-Profit | Type Of Agreement | Product Area | Details (Date) |
Aastrom Biosciences Inc. (ASTM) | The Barbara Ann Karmanos Cancer Institute at Wayne State University | Development agreement | New cell-based therapies | Project will be funded through a $2.2M grant; the work will be done through a Center for Cell Therapy, which will pursue cord blood stem cell therapies for leukemia patients and dendritic cell vaccines for cancer treatment (2/14) |
Advanced Biosystems Inc. (subsidiary of Hadron Inc.) | U.S. Army Medical Research and Material Command | One-year contract | Medical defenses for anthrax | The one-year contract is worth $2.6M (2/22) |
Advanced Viral Research Corp. (OTC BB:ADVR) | Weizmann Institute of Science (Israel) | Research agreement | Immunomodulator and antiviral drug, Product R | Weizmann scientists will investigate the effects of Product R on immune function, especially on T lymphocytes (2/5) |
Affitech A/S (Norway)* | University of Oslo and the Norwegian National Hospital | Exclusive, nine-month option agreement | Troy-bodies | Affitech obtained the option to the vaccine delivery system, Troy-bodies (12/1) |
Affymetrix Inc. (AFFX) | Medical Research Council (UK) | Licensing agreement | Patents for nucleic acid arrays | Affymetrix licensed the patents to make, use and share types of certain nucleic acid arrays for gene expression monitoring; MRC will use the property internally (11/28) |
Altus Biologics Inc.* | Cystic Fibrosis Foundation Therapeutics Inc. | Development agreement | TheraCLEC-Total | Altus is receiving $25M in funding to develop the product for nutrition-starved cystic fibrosis patients (3/7) |
Amersham Pharmacia Biotech* | Georgia Research Alliance | Access agreement | Ettan integrated proteomics technologies | Amersham will provide instrumentation, chemistry and software tools to facilitate proteomics research (3/22) |
Amersham Pharmacia Biotech* | University of Washington's Department of Molecular Biology | Access agreement | SNiPer scoring system | Amersham granted early access to its SNiPer scoring system to the university, which will use it in a validation study focused on typing genetic differences between individuals in the angiotensinogen gene (11/17) |
Amersham Pharmacia Biotech* | Cambridge University (UK) | Access agreement | Proteomics technology | Amersham will provide the university with its proteomics technology to be used to unravel the proteomes of the fruitfly and the mustard plant (12/14) |
Amsterdam Molecular Therapeutics BV (the Netherlands)* | Wisconsin Alumni Research Foundation | License agreement | Gene therapy for familial hypercholesterolemia | AMT gains a license to low-density lipoprotein receptor-related research, with an exclusive option to license future intellectual property in the field (3/1) |
Amylin Pharmaceuticals Inc. (AMLN) | National Institutes of Health | License agreement | Exendin-4 | Amylin gains worldwide rights to patent applications directed to a novel use of exendin-4 to convert noninsulin-producing cells into insulin-producing cells; Amylin agreed to pay license fees (3/19) |
Applied Biosystems Inc. (NYSE:ABI) | University of Washington | Licensing agreement | Isotope-coded affinity tag (ICAT) reagents | Applied obtained an exclusive worldwide license to manufacture and commercialize ICAT reagents; financial terms were ND (11/20) |
Aquasearch Inc. (AQSE) | University of Hawaii | Development agreement | New pharmaceuticals | Scientists will develop new drugs from more than 2,000 strains of microalgae; university will receive royalties on any drug candidates discovered (1/4) |
Athersys Inc.* | Cleveland Clinic Foundation | Collaboration agreement | Cancer and inflammation drug targets | Collaboration is to discover and validate the targets; Athersys has an exclusive option to commercialize novel therapeutics that result (3/9) |
Atrix Laboratories Inc. (ATRX) | Tulane University Health Science Center | Option licensing agreement | Human growth hormone releasing peptide-1 | Atrix will develop the compound for its own product portfolio (1/24) |
Avax Technologies Inc. (AVXT) | French Army | Contract | Clinical trial of Avax's thymidine kinase suicide gene program for prevention of graft-vs.-host disease | Contract is valued at $140,000 (2/5) |
Aviva Biosciences Corp.* | University of California, San Diego, Institute of Molecular Medicine | Collaborative research project | Biochip-based isolation and study of cardiac conduction system | Terms of the agreement were not disclosed (3/2) |
Biokeys Pharmaceuticals Inc. (Pink Sheets: BKYS) | University of Southern California | Option and license agreement | ThioChemistry and the Thiovir product line of antiviral and anticancer compounds | Biokeys exercised its right under the August 2000 agreement for an exclusive worldwide license to the technology (12/19) |
Bio-Rad Laboratories Inc. (AMEX:BIO) | Institut Pasteur (France) | Renewed collaboration | Research developments in virology, microbiology, physiology, biochemistry, parasitology and mycology | The collaboration, begun in 1990, is renewed for four years (3/6) |
BioReliance Corp. (BREL) | National Institute of Allergy and Infectious Diseases | Development and production contract | Viral vectors | The value of the contract is just over $6M; it calls for separately ordered deliverables over a five-year period; the institute expects to use the materials in trials to test gene therapies for infectious diseases (12/14) |
BioTransplant Inc. (BTRN) | Massachusetts General Hospital's Transplantation Biology Research Center | Collaboration renewal | Research in human organ transplant | Parties renewed their agreement for five years to find new approaches to prevent the need for long-term immunosuppressive treatment for human organ transplant patients; BioTransplant will fund a portion of the research in exchange for worldwide royalty-bearing rights to resulting technology and inventions (12/4) |
Carrington Laboratories Inc. (CARN) | Southern Research Institute | Evaluation agreement | CR1013 | Carrington contracted with the institute to evaluate its charged polysaccharide, CR1013, as a drug delivery agent; results are expected in mid-2001 (11/27) |
Celera Genomics (NYSE:CRA) | Sandia National Laboratories | Four-year development agreement | Software and computer hardware for computational biology and life science applications | Compaq Computer Corp. will provide the technology (1/19) |
Celera Genomics (NYSE:CRA) | University of California | Multiyear access agreement | Celera's database products | Financial terms were not disclosed (1/29) |
Celera Genomics (NYSE:CRA) | AMDeC LLC (consortium of 37 of New York's medical schools, academic health institutions and other research institutions) | Multiyear access agreement | Celera's database products | AMDeC will have access to the products through the Celera Discovery System (3/1) |
Cerus Corp. (CERS) | Army Medical Research Acquisition Activity division of the Department of Defense | Cooperative agreement | Pathogen-inactivation technologies | Cerus received a $3.5M award to develop the technologies to improve the safety and availability of blood that may be used in the U.S. Armed Forces for medical transfusions (3/7) |
Charles River Laboratories Inc. (NYSE:CRL) | Tufts University School of Veterinary Medicine | Development and commercialization agreement | Cloning technology | Charles River will sponsor research at Tufts to refine the somatic cell-cloning technique in exchange for an exclusive license to the technoogy in the field of rat, mouse and other rodent research use (12/4) |
Ciphergen Biosystems Inc. (CIPH) | Johns Hopkins University School of Medicine | Multiyear research collaboration | Protein biomarkers for cancer | The collaboration will focus on the discovery and validation of diagnostic markers that improve tumor detection; Ciphergen will provide financial support and technical assistance, and will have commercial rights to the discoveries (11/30) |
Celgene Corp. (CELG) | National Cancer Institute | Cooperative research and development agreement | Celgene's selective cytokine inhibitory drugs (SelCIDs) | The NCI will conduct Phase I and II trials of the most promising SelCID compounds in the five-year agreement (12/7) |
Collateral Therapeutics Inc. (CLTX) | University of California | Exclusive option agreement | Genes related to cell cycle regulation | Collateral will develop and commercialize the research and technology, which gives an option for exclusive worldwide rights to genes and technologies (1/23) |
Collgard Biopharmaceuticals Ltd.* | Mayo Clinic | Collaborative and licensing agreement | Halofuginone | Agreement is for a second collaborative and licensing agreement to further develop the coronary restenosis treatment (2/7) |
CoPharma Inc.* | Dana-Farber Cancer Institute | Agreement for worldwide rights | Beta-Lapachone (CO-501) | Co-Pharma acquired worldwide rights to the compound to treat ovarian, breast and prostate cancers (2/1) |
Copernicus Therapeutics Inc.* | U.S. Naval Medical Research Center | Collaborative research and development agreement | PLASmin Complexes | The parties will explore uses of Copernicus' PLASmin Complexes in the development of a malaria DNA vaccine (12/19) |
Cypress Bioscience Inc. (CYPB) | Sanquin Blood Foundation | Expanded development agreement | Cypress's platelet alternative, Cyplex | Agreement, initiated in Feb. 1998, is for the development of Cyplex up to commercialization (2/14) |
Cytochroma Inc.* | Johns Hopkins University | Research and license agreement | Intellectual property portfolio relating to noncalcemic, antiproliferative and transcriptionally active vitamin D analogues | Agreement is for exclusive and worldwide rights; it also grants rights to Cytochroma on new intellectual property arising from the collaboration (12/7) |
CytRx Corp. (CYTR) | University of Cincinnati Medical Center | Collaboration | CRL-5861 to treat muscular dystrophy | University will study the drug; initial funding for the collaboration will come from a grant from the Muscular Dystrophy Association (1/29) |
Deltagen Inc. (DGEN) | University of Kentucky | Licensing agreement | A new approach to the treatment of acute myelogenous leukemia | Deltagen was granted an exclusive worldwide license to research, develop and commercialize methods and compounds targeting CD123, a marker for certain types of leukemic cells; financial terms were not disclosed (11/27) |
Diversa Corp. (DVSA) | Council for Scientific and Industrial Research | Biodiversity access agreement | Environmental samples from South Africa | Diversa gains the rights to discover genes and commercialize products from the samples; it will support the CSIR's activities and pay royalties on any resulting products (12/7) |
DNAPrint genomics (Pink Sheets:DNAP) | University of Miami | Discovery and development collaboration | Personalized medical products | Collaboration aims to qualify and quantify the genetic and environmental determinants underlying variation of ovarian cancer patient response to chemotherapy (12/13) |
DNA Sciences Inc.* | University of Utah and Yale University | Licensing agreement | 152 variants in five separate genes associated with severe cardiac arrhythmias | DNA Sciences will develop and commercialize clinical management tests for Long QT syndrome (11/16) |
Eliance Biotechnology* | The Center For Biomedical Inventions at the UT Southwestern Medical Center | Licensing agreement | Expression Library Immunization | Eliance gains exclusive development rights for the technology (2/7) |
EluSys Therapeutics Inc.* | University of Virginia | Renewed development agreement | Heteropolymer System | Renewed agreement to further develop the system for the treatment of human diseases (2/15) |
Entigen Corp.* | South African National Bioinformatics Institute | Development agreement | Data sets describing gene expression profiles called Clusterall | The parties will combine their resources to create and deliver the data sets (1/23) |
EntreMed Inc. (ENMD) | National Institute of Allergy and Infectious Diseases | Subcontracting agreement | Malaria vaccine | EntreMed will receive about $1M to $2M per year for seven years for its expertise in the recombinant production of malaria vaccine candidates (11/28) |
EntreMed Inc. (ENMD) | Children's Hospital, Boston | Extended sponsored research agreement | Antiangiogenic agents | EntreMed extended its agreement with the hospital to continue discovery research (12/6) |
Epigenomics AG (Germany)* | Stifterverband fur die Deutsche Wissenschaft | Research project | Activity of genes in the RAS tumor-signaling pathway | Epigenomics is participating in a US$1.39M research project to analyze the activity of genes in the RAS tumor-signaling pathway (3/15) |
Galenica Pharmaceuticals Inc.* | National Institute of Allergy and Infectious Diseases | Preclinical evaluation agreement | Galenica's immunomodulator (adjuvant) technology in the development of a tuberculosis vaccine | Galenica's lead adjuvant candidate, GPI-0100, will be evaluated in vaccine formulations containing mycobacterial antigens (12/12) |
GeneData AG (Switzerland)* | Japanese National Institute of Technology and Evaluation | License agreement | GeneData Phylosopher | The institute will use the technology for the computational analysis of genome sequence data (3/19) |
GeneFormatics Inc.* | Rutgers University | Worldwide license agreement | New nuclear magnetic resonance spectroscopy technology | GeneFormatics gains an exclusive worldwide commercial license to the technology (1/17) |
GeneSoft Inc.* | University of Alberta's chemistry department | Exclusive worldwide license agreement | Patents based on research conducted in the laboratories of William Lown | The patents relate to compounds that recognize and bind to different DNA sequences and are useful as anticancer or antiviral agents (3/21) |
Genetic Technologies Ltd. (OTC BB:GNTLF) | University of Melbourne | Collaboration | Infectious diseases in livestock | Collaboration will pursue a genomics approach to the diagnosis and treatment of infectious diseases in agricultural animals and common worms in domestic animals (1/5) |
Genetic Vectors Inc. (OTC BB:GVEC) | The Cleveland Clinic Foundation | Research and technology transfer agreement | To discover and define genes and nucleic acid sequences related to diseases, therapeutic responses and management | The companies will collaborate to discover genes involved in cardiovascular diseases (2/21) |
Genetronics Biomedical Ltd. (GEB) | Naval Medical Centers | Cooperative research and development agreements | Using electroporation for in vivo gene delivery | Genetronics entered into three agreements to assess the feasibility of using electroporation for in vivo gene delivery (1/31) |
Genomic Solutions Inc. (GNSL) | Duke University, Josephine Ford Cancer Center and Henry Ford Health System | Contract agreements | Genomic and proteomic research | Organizations contracted with Genomic Solutions for genomic and proteomic research to be conducted at its Proteomic Research Center (12/20) |
Genta Inc. (GNTA) | U.S. National Institutes of Health | Exclusive worldwide licensing agreement | Decoy aptamers, a novel type of cancer therapy | Separately, the parties will execute a cooperative research and development agreement to provide funding of further research (12/21) |
GenVec Inc. (GNVC) | Northwestern University | Exclusive license agreement | Pigment epithelium-derived factor | The license is for all ocular gene therapy applications and covers methods invented to inhibit abnormal blood vessel formation (2/12) |
Genzyme General (GENZ) | University of Michigan | Licensing agreement | A class of small-molecule compounds that may be useful in treating lysosomal storage disorders | Terms were not disclosed (11/27) |
Genzyme Molecular Oncology (GZMO) | Bruce Walker, director of the Partners AIDS Research Center at Massachusetts General Hospital | Discovery and research collaboration | HIV antigen | Walker and Genzyme Molecular will conduct research to identify novel peptides that may be used as HIV vaccines (1/10) |
Gilead Sciences Inc. (GILD) | Southern Research Institute | Licensing agreement | 4'-thio-araC, a nucleoside analogue for the treatment of cancer | Gilead gains an exclusive worldwide development and marketing license (12/18) |
GlycoDesign Inc. (Canada; TSE:GD) | Institute for Biological Sciences at the National Research Council | Three-year research collaboration | Surfacecarbohydrates | Collaboration involves the investment of C$4.1M (US$2.7M) in cash to characterize new glycobiology drug targets from a number of medically important bacteria, including Helicobacter pylori (12/19) |
GPC Biotech AG (Germany; OTC BB: GPCBF) | California Institute of Technology/CalTech and Garching Innovation (Germany) | Licensing agreement | Protein-protein interaction intellectual property | The technology, Detection Enhanced Ubiquitin Split Protein Sensor, will be used by GPC for product development and in its drug discovery alliances (11/27) |
GPC Biotech AG (Germany; OTC BB: GPCBF) | Massachusetts General Hospital and the Cold Spring Harbor Laboratory | Licensing agreement | Cyclin-D1 gene and its referring protein | GPC will pay annual license fees to the originators (12/13**) |
Heska Corp. (HSKA) | Torrey Mesa Research Institute | Exclusive evaluation agreement | Heska's proprietary genes | The institute will evaluate the genes for the ability to alleviate and prevent clinical symptoms of allergic disease (2/2) |
Igen International Inc. (IGEN) | National Cancer Institute | Development collaboration | Techniques and products for cancer research | Igen signed a letter of intent for the collaboration, which will use Igen's Origen biological detection technology to detect ubiquitin (2/22) |
Immunicon Corp.* | Fox Chase Cancer Center | Research support agreement | Use of Immunicon diagnostic technology in the monitoring of colon cancer | Agreement also will be to find new targets for screening, diagnosing and managing the disease (1/26) |
Immuno-Designed Molecules SA* (France) | Peter MacCallum Cancer Institute | Collaboration agreement | Extension of IDM's Phase III clinical trial in ovarian cancer | The study will take place over three years and will include 300 ovarian cancer patients (2/15) |
Incyte Inc. (INCY) | The Cardiovascular Research Institute Maastricht at the University of Maastricht (the Netherlands); University of California San Francisco | Genomics research partnership | Cardiovascular disease compounds; prostate cancer compounds | Resulting intellectual property will be jointly owned in each agreement (12/13) |
Incyte Genomics Inc. (INCY) | Gene Ontology Consortium | Collaboration | Scientific standard for describing and querying the function of genes | Incyte made a significant financial contribution to the Gene Ontology Project at Stanford University, a member of the consortium (1/4) |
InforMax Inc. (INMX) | Whitehead Institute for Biomedical Research | Collaboration | Genomic research | The institute has licensed GenoMax from InforMax and will give input for future enhancements (11/17) |
Introgen Therapeutics Inc. (INGN) | Texas Heart Institute | Research agreement | Gene therapy in cardiovascular disease | Study will extend preclinical testing to more complex tissue and animal models of cardiovascular disease (3/14) |
Invitrogen Corp. (IVGN) | The Institute for Genomic Research | Master distribution agreement | Gene clones and clone sets | Invitrogen will have worldwide rights to distribute gene clones and clone sets derived from TIGR's gene libraries (3/21) |
IsoTis NV (the Netherlands)* | Massachusetts Institute of Technology | Extended collaboration | Tissue-engineered cartilage | IsoTis was granted exclusive rights to MIT patents (2/14**) |
Large Scale Biology Corp. (LSBC) | U.S. Navy and National Institutes of Health | Research project | Non-embryonic human stem cell research | Large Scale will produce a stem cell growth factor using its patented tobacco plant-based technology (3/16) |
LigoCyte Pharmaceuticals Inc.* | Montana State University | Development agreement | M Cell vaccine technology | LigoCyte will develop the technology for the delivery of anti-infective agents via oral and nasal routes; company also licensed bacterial and fungal antibodies, proteins, peptides and carbohydrates that have potential prophylactic or therapeutic applications; licenses include up-front fees, sponsorship of research projects, patent costs, stock options and royalties (12/7) |
Magainin Pharmaceuticals Inc. (now called Genaera Corp.; GENR) | Ludwig Institute for Cancer Research (Germany) | Discovery and development collaboration | Novel genes and proteins as pharmaceutical targets and therapeutics | Agreement calls for joint primary commercial rights to intellectual property for a number of novel genes and proteins discovered during joint genomics and biological research conducted under a 1996 agreement (1/31) |
Maxygen Inc. (MAXY) | International AIDS Vaccine Initiative and DBLV LLC | Three-year collaboration | For the development of an HIV vaccine that has activity against a number of HIV strains | Maxygen will use its Molecular-Breeding technology in the collaboration (2/20) |
Microbia Inc.* | Harvard Medical School | Exclusive license agreement | Logic circuits of bacterial biofilm formation | Microbia gained a license to the circuits, as well as compounds and methods for finding compounds that disrupt biofilms; financial terms were not disclosed (11/16) |
Microbia Inc.* | Whitehead Institute for Biomedical | Exclusive license agreement | Fungal biofilm formation | The agreement gives Microbia rights to the formation and means for identifying compounds that inhibit fungal biofilm formation (1/26) |
Modex Therapeutics Ltd. (Switzerland; SSE:MDXN) | Blood Transfusion Center (France) | Exclusive license agreement | Fibrin glue-keratinocyte combinations for wound treatment | Modex gains exlusive rights to the technology in territories other than France (3/14**) |
Nanogen Inc. | Three undisclosed | Beta testing | Nanochip Molecular | The institutions have begun |
(NGEN) | institutions | agreements | Biology Workstation | gene expression beta tests (3/15) |
NaPro BioTherapeutics Inc. (NPRO) | University of Delaware and Thomas Jefferson University | Licensing agreement | Gene alteration technology | NaPro licensed the technology; the agreement includes patent and research funding commitments, as well as NaPro stock; deal is valued at about $1M (12/1) |
NeoPharm Inc. (NEOL) | National Cancer Institute | Development agreement | SS1(dsFv)-PE38 to treat mesothelin-expressing tumors | Parties increased the scope and funding of their collaboration to develop the anticancer agent (3/2) |
Neoprobe Corp. (OTC BB:NEOP) | University of California's San Diego Cancer | Option licensing agreement | Radiolabeled agent designed to improve surgical management and diagnosis of breast cancer | Neoprobe has an option to license the compound from the university (2/14) |
NeoTherapeutics Inc. (NEOT) | NDDO Research Foundation (the Netherlands) | Signed intent to acquire anticancer compound | EO9 and 79 of its analogues | NeoOncoRx, subsidiary of NeoTherapeutics, will receive worldwide rights to the compound it will call Neoquin (1/4) |
Nycomed Amersham plc (UK; NYSE:NYE) | Cleveland Clinic Foundation | Collaboration | Genetic basis for prostate cancer | Nycomed will provide technical support and funding for the foundation's examination of the genetic basis for prostate cancer (11/27) |
Nymox Pharmaceutical Corp. (NYMX) | Faculty of Veterinary Medicine at the University of Montreal | Collaboration | Animal treatments for E. coli 0157:H7 | The parties will study animal treatments for E. coli (1/31) |
Oncology Sciences Corp.* | Tulane University and Colorado State University | Collaborative research agreements | 2-Methoxyestradiol | Collaborations will focus on 2-ME and other antiangiogenesis inhibitors for cancer treatment (12/6) |
Oxford BioMedica plc (UK; LSE:OXB) | French Centre for National Scientific Research University of Montpelier | Technology access agreement | Antibody technology to treat diseases, including cancer | BioMedica will pay an up-front fee, milestones and royalties on sales (2/1) |
Oxford BioMedica plc (UK; LSE:OXB) | King's College | Exclusive rights agreement | RAR beta-2, a gene associated with nerve regeneration | The combination of the gene with Oxford's LentiVector gene delivery system could lead to a product for nerve repair (2/5) |
Oxxon Pharmaceuticals Ltd. (UK)* | Ludwig Institute for Cancer Research | Licensing agreement | Tumor-associated antigens | Oxxon will use the antigens in its therapeutic vaccines program for the treatment of certain cancers (12/13) |
Panacea Pharmaceuticals Inc.* | Massachusetts Institute of Technology | Collaborative research agreement | Fully human, high-affinity single-chain antibodies for Panacea's cancer platform technology | The technology is based on the enzyme aspartyl asparaginylbeta hydroxylase; financial terms were not disclosed (2/7) |
Peregrine Pharmaceuticals Inc. (PPHM) | Paul Scherrer Institut (Switzerland) | Extended research and development agreement | Tumor necrosis therapy-based positron emission tomography imaging agents | The agreement originally focused on scaling up the radio-labeling processes for Peregrine's Cotara and Oncolym monoclonal antibody-based anticancer agents (3/13) |
Pharsight Corp. (PHST) | FDA's Center for Drug Evaluation and Research | Development agreement | Products developed using clinical drug trial simulation and population pharmacokinetic analysis software | The three-year agreement will involve future versions of Pharsight's WinNonMix and Trial Simulator products (2/14) |
PowderJect Pharmaceuticals plc (OTC BB:PWJPF) and its subsidiary Evans Vaccines | UK's Department of Health | Contract | Tuberculosis vaccines for adults and children | The two-year contract covers the vaccines, as well as tuberculin tests used to identify those who require vaccination (3/26) |
Procyon BioPharma Inc. (Canada; OTC BB: PCYBF) | University of Toronto Innovations Foundation | Purchasing agreement | Technology and patents related to Colopath | Procyon finalized an agreement with the foundation for the rapid, noninvasive screening test for colorectal cancer; terms were not disclosed (11/30) |
Progen Industries Ltd. (Australia; PGLAF) | Griffith University | Research collaboration | Heparanase inhibitors to treat inflammatory diseases, including multiple sclerosis and inflammatory bowel disease | Progen will invest up to $1.4M (3/26) |
Proteome Sciences plc (UK; OTC BB: PMSNF) | King's College, Institute of Psychiatry | Collaboration | Neurodegenerative diseases | Proteome will provide protein separation, identification and characterization skills and the institute will provide its expertise in pathogenic mechanisms; Proteome will have the option for an exclusive license agreement to commercialize resulting products (3/26) |
Proteus SA (France)* | CEA-LETI (France) | Partnership | Phenomics-based biochips | The partnership will minitaurize the Phenomics 96-well microtiterplate format into more than 8,000 micro-well biochips (11/27) |
Protogene Laboratories Inc.* | University Health Network (Canada) | Collaboration | Protogene's fully customizable oligonucleotide DNA microarrays | Researchers will use the arrays to validate the arrays in gene expression studies (2/7) |
Qiagen Genomics Inc. (QGENF) | The Institute for Genomic Research and the Montefiore Medical Center | Research and license agreement | Single nucleotide polymorphisms in Mycobacterium tuberculosis | Qiagen gained an exclusive license to make and sell kits or other products based on M. tuberculosis patents (3/15) |
RCT BioVentures NE* | Boston University | Formation of a new company | Sedecim Therapeutics Inc. | RCT and Boston University formed Sedecim to develop interleukin-16 as a therapy for a variety of pathological immune responses (2/1) |
RegeneRx Biopharmaceuticals Inc. (Pink Sheets: RGRX) | National Institutes of Health | Exclusive licensing agreement | Thymosin beta 4 | RegeneRx will make milestone payments and pay royalties on commercialized products in return for exclusive worldwide rights (2/7) |
Repligen Corp. (RGEN) | University of California, San Diego | Licensing agreement | Novel methods for the treatment of mitochondrial disease and autism | Repligen receives exclusive commercial rights to both inventions and will pay UCSD an up-front fee, clinical development milestones and royalties; Repligen also will support two research projects at UCSD (12/14) |
Sangamo BioSciences Inc. (SGMO) | Massachusetts Institute of Technology | Exclusive worldwide rights agreement | Cell-based molecular screening system | The license includes exclusive worldwide rights to patent applications covering the selection and identification of sequencespecific DNA-binding proteins in bacterial cells (3/7) |
Sequenom Inc. (SQNM) | Whitehead Institute Center for Genome Research | Purchase agreement | MassArray system | The institute will implement the technology in its high-throughput single nucleotide polymorphism genotyping projects (1/5) |
SIGA Technologies Inc. (SIGA) | University of California in Los Angeles | Rights agreement | Antibiotic technology | SIGA gained rights to the technology designed to disarm bacteria by interfering with their ability to attach to and colonize human tissue (12/19) |
Silicon Genetics* | Cincinnati Children's Hospital Research Foundation | Licensing agreement | GeNet | The hospital licensed GeNet, Silicon's web-enabled enterprise solution for storing gene expression data and annotated results (11/15) |
Structural GenomiX* | Cystic Fibrosis Foundation | Five-year research collaboration | Cystic fibrosis transmembrane regulator | The $13M agreement is to decipher the 3-dimensional structure of the protein that, when defective, can cause cystic fibrosis (2/8) |
Symphogen A/S (Denmark)* | Boston University | Exclusive license agreement | Symphage technology | Symphogen licensed the technology worldwide from Boston University and will use it to produce recombinant human polyclonal antibodies; the university receives an ownership interest in Symphogen, as well as up-front payments, milestone payments and royalties (3/21) |
Targeted Genetics Corp. (TGEN) | University of Iowa | Licensing and sponsored research agreement | Technologies that increase the efficiency of adeno-associated virus gene transfer vectors | Agreement will allow vectors to be used as a delivery system for genes too large for standard AAV vector delivery (2/1) |
Telik Inc. (TELK) | Arizona Cancer Center at the University of Arizona | Research collaboration | Small-molecule compounds | Agreement is to apply Telik's TRAP chemogenomics technology to identify small-molecule compounds active against multiple cancer targets; Telik will have exclusive worldwide rights to develop and commercialize compounds (1/9) |
TherImmune Research Corp.* | National Institute for Allergies and Infectious Diseases | Seven-year subcontracting agreement | Malaria vaccine | The $43M contract is to provide nonclinical safety and immunogenicity testing of vaccine candidates (11/22) |
Therion Biologics* | International AIDS Vaccine Initiative | Development collaboration | Prophylactic AIDS vaccines for developing countries, specifically India | IAVI will fund Therion's work (3/20) |
Third Wave Technologies Inc. (TWTI) | Catalyst BioMedica Ltd. (UK) and Cambridge University | Research collaboration | Invader operating system-based products | Parties are seeking to discover the genetic differences that predispose certain people to Type I diabetes and other inflammation-related diseases (12/20) |
Third Wave Technologies Inc. (TWTI) | University of Minnesota | Collaboration | Invader operating system for genotyping patient samples | The goal is to validate the association between mutations in the gene believed to be responsible for the development of hemochromatosis (1/5) |
Viragen Inc. (AMEX:VRA) | The Roslin Institute (Scotland) | Collaborative project | Production of drugs inside the eggs of chickens | The project is designed to enable biotech and pharmaceutical companies to produce drugs inside the eggs of specially developed chickens (12/6) |
Vysis Inc. (VYSI) | Mayo Clinic | Renewed research agreement | Diagnostic tests for bladder, lung and prostate cancers | Vysis renewed its agreement, which initially will focus on evaluation of a cellular genomic probe panel under development by Vysis for the early detection of lung cancer (12/14) |
Notes: |
||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. |
||||
* Privately held company ** Denotes the date the item ran in BioWorld International |
||||
Unless otherwise noted, the stock symbols listed are on the Nasdaq market. |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-The-Counter Bulletin Board; NYSE = New York Stock Exchange; SSE = Swiss Stock Exchange; TSE = Toronto Stock Exchange |
||||
